Abstract

Potential of Fixed-Duration Ibrutinib + Venetoclax in High-Risk CLL

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Clinical Outcomes Among Real-World Patients with Chronic Lymphocytic Leukemia (CLL) Initiating First-Line Ibrutinib or Chemoimmunotherapy (CIT) Stratified By Risk Status: Results from a US Retrospective Chart Review Study
Tarun Bhagnani ... Kathleen L Deering
Blood | VOL. 136
Tarun Bhagnani, et. al.Tarun Bhagnani ... Kathleen L Deering
05 Nov 2020
Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)
Richard T Maziarz ... Michael T Maris
Blood | VOL. 116
Richard T Maziarz, et. al.Richard T Maziarz ... Michael T Maris
19 Nov 2010
Lack of the leukocyte-associated Ig-like receptor-1 expression in high-risk chronic lymphocytic leukaemia results in the absence of a negative signal regulating kinase activation and cell division
A Bruzzone ... F Caligaris-Cappio
Leukemia | VOL. 22
A Bruzzone, et. al.A Bruzzone ... F Caligaris-Cappio
21 Feb 2008
Role of Histone Deacetylase-Mediated Gene Silencing in Chronic Lymphocytic Leukemia Progression
Jennifer A Woyach ... Pearlly S Yan
Blood | VOL. 128
Jennifer A Woyach, et. al.Jennifer A Woyach ... Pearlly S Yan
02 Dec 2016
View more papers

More From: Oncology Times

Paper Title
Journal
Date
Author
Deciphering Microbial Markers
Dibash Kumar Das
Oncology Times | VOL. 46
Dibash Kumar DasDibash Kumar Das
01 May 2024
Success of Axicabtagene Ciloleucel in R/R Indolent Non-Hodgkin Lymphoma
Dibash Kumar Das
Oncology Times | VOL. 46
Dibash Kumar DasDibash Kumar Das
01 May 2024
Zanubrutinib Better Tolerated Than Ibrutinib in B-Cell Malignancies
Mark L Fuerst
Oncology Times | VOL. 46
Mark L FuerstMark L Fuerst
01 May 2024
UpToDate®
-
Oncology Times | VOL. 46
--
01 May 2024
View more papers